Results 161 to 170 of about 4,942 (259)

Comprehensive Assessment of PCSK9 Inhibitors for Lipid Management: Scientific Guidance Based on Drug Selection Recommendations for Chinese Medical Institutions

Drug Design, Development and Therapy
Jiabao Li, Siyong Huang, Xiao Hu, Jisheng Chen Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, People’s Republic of ChinaCorrespondence: Jisheng Chen, Key Specialty of Clinical Pharmacy,
Li J, Huang S, Hu X, Chen J
doaj  

Fast Decline of Low-Density Lipoprotein Cholesterol after a First Dose of Inclisiran: A Case Report [PDF]

Laura Schnetzer
openalex   +1 more source

Inclisiran—New hope in the management of lipid disorders? [PDF]

, 2019
Krzysztof Dyrbuś, Mariusz Gąsior, Peter E. Penson, Kausik K. Ray, Maciej Banach   +4 more
openalex   +1 more source

An Inclisiran First Strategy vs Usual Care in Patients with Atherosclerosis.

Journal of the American College of Cardiology
Michael J. Koren, Fatima Rodriguez, Cara East, Peter P. Toth, Veena Watwe, C. Abbas, S. Sarwat, K. Kleeman, Biswajit Kumar, Y. Ali, Naseem Jaffrani   +10 more
semanticscholar   +1 more source

Safety and Lipid-Lowering Efficacy of Inclisiran Monotherapy in Patients without ASCVD: The VICTORION-Mono Randomized Clinical Trial.

Journal of the American College of Cardiology
Pam R. Taub, Alexis Gutierrez, Donavon L. Wewers, Elias Garcia Cantu, Hui Cao, C. Deck, A. Lesogor, Denise Ott, Jorge Mena-Madrazo, Xiao Zang, R. S. Wright   +10 more
semanticscholar   +1 more source

7-021 Impact of bempedoic acid, icosapent ethyl, inclisiran and monoclonal PCSK9 inhibitors on lipids in a real-world setting [PDF]

Sophia Khattak, Antonio Ochoa‐Ferraro, Nazish Khan, Sudhakar George, Sohail Q. Khan, John Townend, Charlotte Dawson, Mark R. Thomas   +7 more
openalex   +1 more source

Inclisiran-Induced Fixed Drug Eruption in a Patient With Refractory Hypercholesterolemia. [PDF]

Cureus
Khan JA, Shahab S.
europepmc   +1 more source

ORION-8: one step closer to understanding the safety and efficacy of inclisiran [PDF]

Norata, Giuseppe Danilo, Tokgözoğlu, Lale   +1 more
core   +1 more source

Paradoxical LDL-C Increase after Switching from PCSK9 Inhibitors to Inclisiran: A Real-World Case Series. [PDF]

Acta Cardiol Sin
Chua SK, Hung HF, Jong BH, Chen LC.
europepmc   +1 more source

Real-world experience of inclisiran up to 27 months from initiation [PDF]

Matthew Waite, Rehan Aftab, Edmund Wilkes, Shahenaz Walji, Lucy Barton, Kausik K. Ray, Ferruccio De Lorenzo, Alessia David, Ben Jones, Jaimini Cegla   +9 more
openalex   +1 more source